Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Exp Cell Res. 2020 Jul 1;392(1):112015. doi: 10.1016/j.yexcr.2020.112015. Epub 2020 Apr 22.
N6-methyladenosine (m6A) has been reported to be involved in several biological processes in tumors. In this study, we found that most of the m6A RNA methylation regulators were not only differentially expressed between clear cell renal cell carcinoma (ccRCC) and normal but also among ccRCC stratified by different clinicopathologic characters. Two ccRCC subgroups, cluster 1 and 2, were identified using consensus clustering based on the expression of m6A methylation regulators. Although no obvious differences were observed between two subgroups regarding clinicopathologic characters, except gender, patients in cluster 1 had a relatively more favorable survival rate than cluster 2. Moreover, we established a risk signature with two m6A methylation regulators, METTL3 and METTL14, which was not only of great value for prognosis prediction but also closely associated with clinicopathological features. In conclusion, m6A RNA methylation regulators play an important role in ccRCC progression and are potentially favorable for prognostic stratification.
N6-甲基腺苷（m6A）已被报道参与肿瘤中的几种生物学过程。在这项研究中，我们发现大多数 m6A RNA 甲基化调节剂不仅在透明细胞肾细胞癌（ccRCC）与正常组织之间存在差异表达，而且在根据不同临床病理特征分层的 ccRCC 中也存在差异表达。基于 m6A 甲基化调节剂的表达，使用共识聚类方法鉴定出两个 ccRCC 亚群，簇 1 和簇 2。尽管除性别外，两个亚组之间的临床病理特征没有明显差异，但簇 1 中的患者的生存率相对高于簇 2。此外，我们建立了一个由两个 m6A 甲基化调节剂（METTL3 和 METTL14）组成的风险特征，该特征不仅对预后预测具有重要价值，而且还与临床病理特征密切相关。总之，m6A RNA 甲基化调节剂在 ccRCC 进展中发挥重要作用，并且可能有利于预后分层。
